Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Deborah Collyar: What's In It for Patients?

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Apr

Today In Oncology

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Deborah Collyar: What's In It for Patients?

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Combined Tests Could Avoid Unnecessary Cystectomy, Study Finds

American Cancer Society Announces New Pediatric Adolescent and Young Adult Cancer Journal

Colorectal Cancer Duloxetine Not Effective in Preventing Oxaliplatin-Induced Peripheral Neuropathy

Advanced Prostate Cancer Radiographic Progression and PSA Increase in Patients Treated With Enzalutamide

CLL Linked to Increased Skin Cancer Risk and Mortality